Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life Current Medical Research and Opinion, 38 (8) (2022), pp. 1361-1368 CrossrefView in ScopusGoogle Scholar [26] F. Facchinetti, M. Di Maio,...
NSCLC is the most common type of lung cancer, accounting for approximately 85% of the cases. The three most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma as well as large cell carcinoma [7,8,9]. Common cancer treatment approaches include surgery, chemotherapy, and radiation ...
and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [1]. Unfortunately, the majority of NSCLC patients are diagnosed at advanced stages, resulting in a poor prognosis for these individuals [2,3]. Recently, several carcinogenic...
Is traditional Chinese herbal medicine effective in prolonging survival times in extensive-stage small-cell lung cancer patients?BioreaktorenSimulationNo abstract is available for this article.doi:10.1016/j.imr.2015.09.004LeemKorean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine ...
Strasbourg, France; 2Service de Pneumologie Lyautey, Hoˆpitaux Universitaires, 1, Place de l'Hoˆpital, 67091 Strasbourg, Cedex, France Addition of chemotherapy to the treatment of non-small-cell lung cancer (NSCLC) resulted in a modest but clear improvement in the survival of selected pa...
Non-small cell lung cancer AFP: α-fetoprotein PDAC: Pancreatic ductal adenocarcinoma CP: Chronic pancreatitis dsDNA: Double-stranded DNA DCs: Dendritic cells MART1: Melanoma antigen recognized by T cells 1 CTLs: Cytotoxic T lymphocytes MDSCs: ...
Paclitaxel was the first identified member of a new class of anticancer drugs known as the taxanes. This compound has significant single-agent activity against a number of solid tumors including nonsmall cell lung cancer (NSCLC). In the first-line setting, single-agent paclitaxel has been studied...
Lung adenocarcinoma LUSC: Lung squamous cell carcinoma MET: Mesenchymal‐to‐epithelial transition miRNA: MicroRNA mL: Milliliter mNSCLC: Metastatic non-small cell lung cancer MPR: Major pathologic response MRD: Minimal residual disease N: Number ...
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide, necessitating the identification of novel therapeutic targets. Lysosome Associated Protein Transmembrane 4B (LAPTM4B) is involved in biological processes critical t
J Nanobiotechnol (2021) 19:245 https://doi.org/10.1186/s12951-021-00977-3 Journal of Nanobiotechnology RESEARCH Open Access A novel multi‑functionalized multicellular nanodelivery system for non‑small cell lung cancer photochemotherapy Yongtai Zhang1†, Qing Xia1†, Tong Wu1†,...